Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant ...

TOKYO -- As Takeda Pharmaceutical readies new drugs expected to generate billions of dollars in revenue, recent staff and R&D cutbacks have raised questions about the future of its pipeline.

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE). The US regulator has cleared ...

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug target in amyotrophic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ramelteon acts as an MT 1 and MT 2 melatonin receptor agonist, showing higher affinities for these receptors than does the natural ligand Ramelteon induces sleep initiation and maintenance, as ...

Wildfires continue to blaze across Los Angeles, leaving nearly 400,000 residents without electricity and forcing over 70,000 to leave the area under a mandatory evacuation order. Market Domination ...

Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502), announced it is working with the European Medicines Agency (EMA) to voluntarily withdraw the marketing authorization of Alofisel ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...